FrancophonIA/ELRC3.0 huggingface dataset:
English: Concurrent use of indinavir with herbal preparations containing St John's wort (Hypericum perforatum) is contraindicated (see section 4.5).
Maltese: L-użu fl-istess ħin ta' indinavir ma' preparazzjonijiet erbali li fihom St John's wort (Hypericum perforatum) huwa kontra-indikat (ara sezzjoni 4.5).
English: Nephrolithiasis has occurred with indinavir therapy in adult patients with a cumulative frequency of 12.4 % (range across individual trials: 4.7 % to 34.4 %).
Maltese: Nefrolitjasis u nefrajtis tubulointerstizjali Nefrolitijasis seħħet b'terapija b'indinavir f'pazjenti adulti bi frekwenza kumulattiva ta' 12.4 % (firxa fost il-provi individwali: 4.7 % sa 34.4 %).
English: Dose reduction of CRIXIVAN to 400-600 mg every 8 hours should be considered.
Maltese: Għandu jitqies tnaqqis fid-doża ta' CRIXIVAN għal 400-600 mg kull 8 sigħat.
English: Stavudine AUC: ↑ 21 % Stavudine Cmin: not evaluated
Maltese: AUC Stavudine: ↑ 21% Cmin Stavudine: mhux evalwat
English: SEDATIVES/HYPNOTICS Buspirone
Maltese: SEDATTIVI/IPNOTIĊI
English: Seven major metabolites were identified and the metabolic pathways were identified as glucuronidation at the pyridine nitrogen, pyridine-N-oxidation with and without 3'-hydroxylation on the indane ring, 3'-hydroxylation of indane, p-hydroxylation of phenylmethyl moiety, and N-depyridomethylation with and without the 3'-hydroxylation.
Maltese: Ġew identifikati seba' metaboliti prinċipali u l-mogħdijiet metaboliċi ġew identifikati bħala glukuronidazzjoni ta' pyridine nitrogen, pyridine-N-oxidation bl-3'-idrossilazzjoni fuq l- indane ring jew mingħajru, 3'- idrossilazzjoni ta' indane, p-idrossilazzjoni ta' phenylmethyl moiety, u Ndepyridomethylation bl-3'- idrossilazzjoni jew mingħajru.
English: • atorvastatin, rosuvastatin, pravastatin, fluvastatin - used to lower cholesterol
Maltese: • atorvastatin, rosuvastatin, pravastatin, fluvastatin - jintużaw biex ibaxxu l-kolesterol
English: ANTIDEPRESSANTS Venlafaxine 50 mg TID (Indinavir 800 mg SD)
Maltese: Venlafaxine 50 mg TID (Indinavir 800 mg SD)
English: CRIXIVAN contains lactose
Maltese: CRIXIVAN fih lactose
English: Phenytoin may decrease serum levels of ritonavir.
Maltese: Phenytoin jista' jnaqqas il livelli fis-serum ta' ritonavir.
English: Children and adolescents CRIXIVAN is not recommended in children under the age of 18 years.
Maltese: Tfal u adolexxenti CRIXIVAN mhuwiex rrakkomandat fi tfal taħt l-età ta' 18-il sena.
English: Acute haemolytic anaemia
Maltese: Anemija emolitika akuta
English: CRIXIVAN 400 mg - packs of 90 and 180 capsules - Bottle label
Maltese: CRIXIVAN 400 mg - pakketti ta' 90 u 180 kapsula - Tikketta tal-flixkun
English: Indinavir AUC and Cmin: ↔ (Relative to Indinavir 400 mg SD)  Quinidine concentration expected (CYP3A4 inhibition by indinavir)
Maltese: AUC u Cmin Indinavir: ↔ (Għal Indinavir 400 mg SD)  fil-konċentrazzjoni ta' Quinidine mistennija (inibizzjoni ta' CYP3A4 minn indinavir)
English: myalgia myositis, rhabdomyolysis, increased CPK, osteonecrosis (see section 4.4), periarthritis.
Maltese: mijalġja mijosite, rabdomijalisi, żieda fis-CPK, ostejonekrożi (ara sezzjoni 4.4), artrite madwar ġog.
English: Pharmacokinetic analysis in one study was performed on nineteen of the patients, with a median (range) indinavir AUC 0-12hr, Cmax, and Cmin of 25,421 nM*h (21,489 - 36,236 nM*h), 5,758 nM (5,056 - 6,742 nM) and 239 (169 - 421 nM), respectively.
Maltese: Analiżi farmakokinetika fi studju wieħed twettqet fuq dsatax-il pazjent, b'AUC 0-12hr, Cmax, u Cmin medja (medda) ta' indinavir ta' 25421 nM*h (21489-36236 nM*h), 5758 nM (5056-6742 nM) u 239 (169-421 nM), rispettivament.
English: In zidovudine experienced patients, indinavir, zidovudine and lamivudine in combination compared with lamivudine added to zidovudine reduced the probability of AIDS defining illness or death (ADID) at 48 weeks from 13 % to 7 %.
Maltese: F'pazjenti li diġa` kienu jieħdu ziduvudine, meta indinavir, zidovudine u lamivudine ittieħdu flimkien u dan tqabbel ma' lamivudine miżjud ma' zidovudine, kien hemm tnaqqis tal-probabbilta` ta' mwiet jew mard minħabba AIDS (ADID) fit-48 ġimgħa minn 13 % għal 7 %.
English: This medicinal product contains 299.2 mg of lactose in each 800 mg dose (maximum single dose).
Maltese: Lactose Il-prodott mediċinali fih 299.2 mg ta' lactose f'kull doża ta' 800-mg (doża singola massima).
English: Interaction study with Lopinavir/ritonavir + rosuvastatin:
Maltese: Lopinavir/ritonavir +
English: By intent to treat analysis 65 % of patients had HIV RNA < 400 copies/mL and 50 % had viral load < 50 copies/mL; by on-treatment analysis 96 % of patients had HIV RNA < 400 copies/mL and 74 % had viral load < 50 copies/mL.
Maltese: B'intenzjoni li tiġi ttrattata analiżi, 65 % tal-pazjenti kellhom HIV RNA <400 kopja/mL u 50 % kellhom tagħbija virali < 50 kopja/mL; b'analiżi fuq it-trattament 96 % tal-pazjenti kellhom HIV RNA <400 kopja/mL u 74 % kellhom tagħbija virali <50 kopja/mL.
English: Asymptomatic pyuria of unknown etiology was noted in 10.9 % (6/55) of paediatric patients who received CRIXIVAN.
Maltese: Materja fl-awrina mingħajr sintomi minn etjoloġija mhux magħrufa kienet innutata f'10.9 % (6/55) tal-pazjenti pedjatriċi li rċivew CRIXIVAN.
English: • The other ingredients are anhydrous lactose, magnesium stearate, gelatin and titanium dioxide
Maltese: • Is-sustanzi l-oħra huma anhydrous lactose, magnesium stearate, ġelatina u titanium dioxide
English: Indinavir at concentrations of 25 to 100 nM mediated 95 % inhibition of viral spread in cultures of mitogen-activated human peripheral blood mononuclear cells infected with diverse, primary clinical isolates of HIV 1, including isolates resistant to zidovudine and nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Maltese: Indinavir f'konċentrazzjonjiet minn 25 sa 100 nM immedja95 % ta' l-inibizzjoni tal-firxa virali f'kulturi ta' ċelluli mononukleari periferali tad-demm uman attivati bil-mitoġen infettati b'iżolati kliniċi primarji diversi ta' l-HIV-1, inkluż iżolati reżistenti għal zidovudine u inibituri mhux nukleosidi reverse transkriptase (NNRTIs).
English: CRIXIVAN contains a substance called indinavir.
Maltese: CRIXIVAN fih sustanza msejħa indinavir.
English: Ritonavir may induce glucuronidation of methadone.
Maltese: Ritonavir jista' jwassal għal glukuronizzazzjoni tal-methadone.
English: For information regarding diet or the effect of food on indinavir absorption (see sections 4.2 and 5.2).
Maltese: Għal informazzjoni dwar id-dieta jew l-effett ta' ikel fuq l-assorbiment ta' indinavir (ara sezzjonijiet 4.2 u 5.2).
English: Saquinavir AUC:  500 % Saquinavir Cmin:  190 % (Relative to saquinavir 600 mg SD (hard gel formulation) alone)
Maltese: AUC Saquinavir:  500% Saquinavir Cmin:  190% (Għal saquinavir 600 mg SD (formulazzjoni b'ġell iebes waħdu)
English: At week 4, the indinavir Cmin was 500 ng/mL with substantial trough variability (range 5 to 8,100 ng/mL).
Maltese: F'ġimgħa 4, il-Cmin ta' indinavir kien 500 ng/mL b'varjabilità minima sostanzjali (medda ta' 5 sa 8100 ng/mL).
English: Antiretroviral activity was unaltered when didanosine was administered 3 hours after treatment with indinavir.
Maltese: L-attività antiretrovirali ma kinitx mibdula meta didanosine ngħata 3 sigħat wara t-trattament b'indinavir.
English: Ritonavir AUC ↓ 36 % Ritonavir Cmin: 39 %
Maltese: AUC Ritonavir:  96% Ritonavir Cmin:  371%
English: The capsules are semi-translucent white and coded ‘CRIXIVAN ™ 200 mg' in blue.
Maltese: Il-kapsuli huma bojod semi-trasluċidi u kkodifikati ‘CRIXIVAN™ 200 mg' fil-blu.
English: • oral contraceptive medicines (‘The Pill') containing norethindrone or ethinyl estradiol
Maltese: • mediċini kontraċettivi li jittieħdu mill-ħalq (‘Il-Pill') li fihom norethindrone jew ethinyl estradiol
English: 3; and the mean increase in percent CD4 cell counts was 4.2 %.
Maltese: 3; iż-żieda prinċipali fil-persentaġġ ta' l-għadd ta' ċelluli CD4 kienet ta' 4.2 %.
English: In one comparative trial, combination therapy with nucleoside analogues (triple therapy with zidovudine plus didanosine) conferred protection against the selection of virus expressing at least one resistanceassociated amino acid substitution to both indinavir (from 13/24 to 2/20 at therapy week 24) and to the nucleoside analogues (from 10/16 to 0/20 at therapy week 24).
Maltese: Fi prova komparattiva, it-terapija kombinata b'nukleosidi analogi (kura tripla b' zidovudine u didanosine) tat protezzjoni kontra l-għażla ta' virus li kellhom mill-inqas reżistenza waħda marbuta ma' sostituzzjoni amino aċida kemm lil indinavir (minn 13/24 sa 2/20 fl-24 ġimgħa ta' kura) kif ukoll lin-nukleosidi analogi (minn 10/16 sa 0/20 fl-24 ġimgħa ta' kura).
English: Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitor, ATC code JO5AE02
Maltese: Antivirali għall-użu sistemiku, inibitur tal-protease, Kodiċi ATC
English: Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of indinavir resulting in approximately 60 % higher mean AUC following a 400-mg dose.
Maltese: Pazjenti li għandhom insuffiċenza tal-fwied minn-ħafif-sa-moderat u evidenza klinika ta' ċirrożi kellhom evidenza ta' tnaqqis tal-metaboliżmu ta' indinavir li wassal għal bejn wieħed u ieħor medja ogħla ta' 60 % AUC wara doża ta' 400-mg.
English: (Relative to Indinavir 800 mg TID alone)
Maltese: (Indinavir 800 mg TID)
English: Indinavir AUC: ↑ 53 % Indinavir Cmin ↑ 298 % (Relative to Indinavir 800 mg TID alone)
Maltese: AUC Indinavir: ↑ 53% Cmin Indinavir ↑ 298% (Għal Indinavir 800 mg TID waħdu)
English: 90 hard capsules 180 hard capsules
Maltese: 180 kapsula iebsa
English: Another published study evaluated the efficacy and safety of indinavir/ritonavir 400/100 mg every 12 hours in 40 antiretroviral-naïve patients.
Maltese: Studju ieħor ippubblikat evalwa l-effikaċja u s-sigurtà ta' indinavir/ritonavir 400/100 mg kull 12-il siegħa f'40 pazjent li qatt ma kienu ħadu antiretrovirali.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Maltese: Pazjenti bi problemi rari ereditarji ta' intolleranza ta' galactose, defiċjenza ta' Lapp lactase jew assorbiment hażin ta' glucose-galactose m'għandhomx jieħdu din il-mediċina.
English: Saquinavir AUC:  360 % Saquinavir Cmin:  450 % (Relative to saquinavir 1,200 mg (soft gel formulation) alone)
Maltese: AUC Saquinavir:  360% Saquinavir Cmin:  450% (Għal saquinavir 1200 mg (formulazzjoni b'ġell artab) waħdu)
English: ANALGESICS Methadone 20-60 mg QD (Indinavir 800 mg TID)
Maltese: ANALĠESIĊI Methadone 20-60 mg QD (Indinavir 800 mg TID)
English: If indinavir is given with ritonavir, the potential interaction may be increased.
Maltese: Jekk indinavir jingħata ma' ritonavir, l-interazzjoni potenzjali tista' tikber.
English: ANTICONVULSANTS Carbamazepine
Maltese: Carbamazepine
English: • theophylline - used for asthma
Maltese: • theophylline - jintuża għall-ażżma
English: In controlled clinical trials conducted world-wide, indinavir was administered alone or in combination with other antiretroviral agents (zidovudine, didanosine, stavudine, and/or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males (15 % females).
Maltese: Fi provi kliniċi kkontrollati li saru madwar id-dinja, indinavir ingħata waħdu jew flimkien ma' aġenti oħra antiretrovirali (zidovudine, didanosine, stavudine, u/jew lamivudine) li bejn wieħed u ieħor 2000 pazjent, li l-maġġoranza tagħhom kienu rġiel adulti Kawkażiċi (15 % nisa).
English: Date of first authorisation: 04 October 1996 Date of latest renewal: 18 July 2011
Maltese: Data tal-aħħar tiġdid: 18 ta' Lulju 2011
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Maltese: Eżempji relevanti huma : retinite ċitomegalovirus, infezzjonijiet mikobatterjali ġeneralizzati u/jew fokali, u pulmonite Pneumocystis carinii.
English: CsA levels require progressive dose adjustment using therapeutic medicinal product monitoring.
Maltese: Il-livelli CsA jeħtieġu aġġustament progressiv fid-doża permezz ta' monitoraġġ terapewtiku tal-prodott mediċinali.
English: The following effects may happen:
Maltese: Madankollu huwa importanti ħafna li inti:
English: CRIXIVAN with or without ritonavir should not be administered concurrently with amiodarone, terfenadine, cisapride, astemizole, quetiapine, alprazolam, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), pimozide, ergot derivatives, simvastatin or lovastatin (see section 4.4).
Maltese: CRIXIVAN bi jew mingħajr ritonavir ma għandux jingħata fl-istess ħin ma' amiodarone, terfenadine, cisapride, astemizole, quetiapine, alprazolam, triazolam, midazolam mogħtija mill-ħalq (għal kawtela fuq midazolam mogħti b'mod parenterali, ara sezzjoni 4.5), pimozide, derivattivi ergot, simvastatin jew lovastatin (ara sezzjoni 4.4).
English: Interaction not studied  dexamethasone exposure expected (CYP3A inhibition).
Maltese: ↑ mistennija espożizzjoni ta' dexamethasone (inibizzjoni ta' CYP3A).
English: • amlodipine, felodipine, nifedipine, nicardipine, digoxin, diltiazem - used for high blood pressure and some heart problems.
Maltese: • amlodipine, felodipine, nifedipine, nicardipine, digoxin, diltiazem - jintużaw għal pressjoni għolja u xi problemi fil-qalb
English: Other medicines and CRIXIVAN
Maltese: Mediċini oħra u CRIXIVAN
English: Saquinavir AUC:  620 % Saquinavir Cmin:  450 % (Relative to saquinavir 800 mg SD (soft gel formulation) alone)
Maltese: AUC Saquinavir:  620% Cmin Saquinavir:  450% (Għal saquinavir 800 mg SD (formulazzjoni b'ġell artab waħdu)
English: Capsule shell: gelatin titanium dioxide (E 171) printing ink: indigo carmine (E 132).
Maltese: Kontenut tal-kapsula anhydrous lactose magnesium stearate qoxra tal-kapsula: ġelatina titanium dioxide (E 171) inka għall-istampar: indigo carmine (E 132).
English: Methadone AUC and Cmin: 
Maltese: AUC u Cmin Methadone: 
English: At steady state following a dose regimen of 800 mg/100 mg of indinavir/ritonavir every 12 hours with a low-fat meal, healthy volunteers in one study achieved geometric means: AUC0-12h 116,067 nM*h (90 % confidence interval = 101,680, 132,490), peak plasma concentrations 19,001 nM (90 % confidence interval = 17,538, 20,588), and plasma concentrations at 12 hours post dose 2,274 nM (90 % confidence interval = 1,701, 3,042).
Maltese: Fi stat fiss wara kura b'doża ta' 800 mg/100mg b'indinavir/ritonavir kull 12-il siegħa wara ikla bi ftit xaħam, f'studju wieħed voluntiera f'saħħithom kellhom medji ġeometriċi ta': AUC0-12h 116067 nM*h (intervall tad-90 % = 101680, 132490), l-ogħla konċentrazzjonijiet tal-plażma ta' 19001 nM (intervall tad-90 % = 17538, 20588), u konċentrazzjonijiet tal-plażma 12-il siegħa wara d-doża ta' 2274 nM (intervall tad-90 % = 1701, 3042).
English: EU/1/96/024/001 EU/1/96/024/002 EU/1/96/024/003
Maltese: EU/1/96/024/003
English: Rosuvastatin AUC  2.08-fold Rosuvastatin Cmax  4.66-fold (Mechanism unknown)
Maltese: Cmax Rosuvastatin ↑ 4.66 -il darba
English: Ritonavir may increase digoxin levels due to modification of P-glycoprotein mediated digoxin efflux.
Maltese: digoxin medjati b'Pglycoprotein.
English: Efavirenz 600 mg QD (Indinavir/ritonavir 800/100 BID)
Maltese: Efavirenz 600mg QD (Indinavir/ritonavir 800/100
English: Mean urinary excretion of unchanged medicinal product following single dose administration in the fasted state was 10.4 % following a 700-mg dose, and 12.0 % following a 1,000-mg dose.
Maltese: Ilmedja ta' tneħħija fl-urina tal-prodott mediċinali mhux mibdul wara l-amministrazzjoni ta' doża waħda waqt sawm kienet ta' 10.4 % wara doża ta' 700-mg, u ta' 12 % wara doża ta' 1,000-mg.
English: In clinical trials in paediatric patients (≥ 3 years), the adverse reaction profile was similar to that for adult patients except for a higher frequency of nephrolithiasis of 29 % (20/70) in paediatric patients treated with CRIXIVAN.
Maltese: Fi provi kliniċi f'pazjenti pedjatriċi (≥ 3 snin), il-profil ta' reazzjonijiet avversi kien jixbah lil dak ta' pazjenti adulti minbarra l-frekwenza ogħla ta' nefrolitjasi ta' 29 % (20/70) f'pazjenti pedjatriċi kkurati bi CRIVAXAN.
English: Efavirenz AUC and Cmin : ↔
Maltese: AUC Indinavir and Cmin: ↔
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Maltese: Ir-rekwiżiti tar- rapporti perjodiċi aġġornati dwar is-sigurtà għal dan il-prodott mediċinali huma mniżżla fil-lista tad-dati ta' referenza tal-Unjoni (lista EURD) prevista skont l-Artikolu 107c(7) tadDirettiva 2001/83/KE u kwalunke aġġornament sussegwenti ppubblikati fuq il-portal elettroniku
English: Rare (≥ 1/10,000 to  1/1,000); Very rare (< 1/10,000); not known (cannot be estimated from the available data).
Maltese: Rari (≥1/10,000 sa < 1/1,000);
English: Limited data are available on the pharmacokinetics of indinavir in association with low dose ritonavir.
Maltese: Hemm data limitata dwar il-farmakokinetika ta' indinavir f'assoċjazzjoni ma' ritonavir ta' doża baxxa.
English: When CRIXIVAN is used with ritonavir, consult the Summary of Product Characteristics of ritonavir for additional contraindications.
Maltese: Meta CRIXIVAN jintuża ma' ritonavir, ikkonsulta s-Sommarju tal-Karatteristiċi tal-Prodott ta' ritonavir għal kontraindikazzjonijiet addizzjonali.
English: In the intent to treat and on treatment analyses the proportion of patients with HIV RNA of < 50 copies/mL was 68.8 % and 88.7 %, respectively, at week 96.
Maltese: Fl-intenzjoni li tiġi ttrattata l-analiżi u waqt it-trattament tagħha, il-proporzjon ta' pazjenti b'HIV RNA ta' <50 kopja/mL kien ta' 68.8% u 88.7%, rispettivament, fil-ġimgħa 96.
English: Indinavir Cmin :↔
Maltese: Indinavir: ↔
English: See Section 3 below for information on how to take CRIXIVAN.
Maltese: Ara Sezzjoni 3 taħt għal informazzjoni dwar kif għandek tieħu CRIXIVAN.
English: Interaction with indinavir/ritonavir not studied  dexamethasone exposure expected (CYP3A inhibition).
Maltese: Interazzjoni mhux studjata ↑ mistennija espożizzjoni għal dexamethasone (inibizzjoni CYP3A).
English: Each hard capsule contains indinavir sulphate corresponding to 400 mg of indinavir.
Maltese: Kull kapsula iebsa fiha indinavir sulphate li huwa ekwivalenti għal 400 mg ta' indinavir.
English: • CRIXIVAN - two 200 mg capsules (400 mg) - taken twice a day.
Maltese: CRIXIVAN - żewġ kapsuli ta' 200 mg (400 mg) - jittieħdu darbtejn kuljum.
English: Isolated asymptomatic hyperbilirubinaemia (total bilirubin  2.5 mg/dL, 43 mcmol/L) was reported predominantly as elevated indirect bilirubin and rarely associated with elevations in ALT, AST, or alkaline phosphatase, has occurred in approximately 14 % of patients treated with CRIXIVAN alone or in combination with other antiretroviral agents.
Maltese: Iperbilirubinimja iżolata mingħajr sintomi (bilirubin totali ≥ 2.5 mg/dL, 43 mkmol/L) kienet irrappurtata l-aktar bħala livelli għoljin ta' bilirubin indirett u kienet assoċjata b'mod rari ma' livelli għolijin ta' ALT, AST jew alkaline phosphatase, seħħet f'madwar 14 % tal-pazjenti kkurati bi CRIXIVAN waħdu jew flimkien ma' sustanzi antiretrovirali oħra.
English: Medicinal products listed above are not repeated in Table 1 and 2 unless specific interaction data is available.
Maltese: Prodotti mediċinali elenkati fuq mhumiex ripetuti fit-Tabella 1 u 2 sakemm ma tkunx disponibbli dejta speċifika.
English: Vardenafil AUC: ↑ 16-fold
Maltese: AUC Vardenafil: ↑ 16-il darba L-għoti fl-istess ħin ta'
English: No specific interaction studies have been performed with the boosted dose 400 mg indinavir with 100 mg ritonavir.
Maltese: Ma sar ebda studju speċifiku dwar l-interazzjoni bid-doża msaħħa ta' 400 mg indinavir b'100 mg ritonavir.
English: In some patients, resolution of the interstitial nephritis did not occur following discontinuation of indinavir therapy; renal insufficiency, renal failure, leucocyturia (see section 4.4).
Maltese: nefrite tal-interstizju wara li twaqqfet it-terapija b'indinavir, ma seħħx; insuffiċjenza renali, falliment renali, lewkoċiturja (ara sezzjoni 4.4).
English: Concomitant use of medicinal products that are inducers of CYP3A4, such as carbamazepine, phenobarbital and phenytoin may reduce indinavir plasma concentrations.
Maltese: Użu fl-istess ħin ta' prodotti mediċinali li huma indutturi ta' CYP3A4, bħal carbamazepine, phenobarbital u phenytoin jistgħu jnaqqsu lkonċentrazzjonijiet tal-plażma ta' indinavir.
English: Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0) 9 804 650 info@msd.fi
Maltese: +358 (0) 9 804 650 info@msd.fi
English: ANTIARRTHYMICS Digoxin 0.4 mg SD Ritonavir 200 mg BID
Maltese: ANTIARRITTMIĊI Digoxin 0.4 mg SD
English: In addition, indinavir with ritonavir must not be administered with alfuzosin, meperidine, piroxicam, propoxyphene, bepridil, encainide, flecanide, propafenone, quinidine, fusidic acid, clozapine, clorazepate, diazepam, estazolam and flurazepam.
Maltese: Barra minn hekk, indinavir ma' ritonavir ma għandux jingħata ma' alfuzosin, meperidine, piroxicam, propoxyphene, bepridil, encainide, flecanide, propafenone, quinidine, fusidic acid, clozapine, clorazepate, diazepam, estazolam u flurazepam.
English: Indinavir was rapidly eliminated with a half-life of 1.8 hours.
Maltese: Indinavir tneħħa malajr b'half life ta' 1.8 sigħat.
English: Adequate hydration is recommended in all patients on indinavir (see sections 4.2 and 4.8).
Maltese: Hija rakkomandata l-idratazzjoni adegwata tal pazjenti kollha li jkunu qed jieħdu indinavir (ara sezzjonijiet 4.2 u 4.8).
English: In addition, indinavir with ritonavir should not be administered with alfuzosin, meperidine, piroxicam, propoxyphene, bepridil, encainide, flecanide, propafenone, quinidine, fusidic acid, clozapine, clorazepate, diazepam, estazolam and flurazepam.
Maltese: meperidine, piroxicam, propoxyphene, bepridil, encainide, flecanide, propafenone, quinidine, fusidic acid, clozapine, clorazepate, diazepam, estazolam u flurazepam.
English: • It is important for adults to drink at least 1.5 litres of liquid each day while taking CRIXIVAN.
Maltese: Importanti li l-adulti jixorbu mill-inqas litru u nofs ta' likwidu kuljum waqt li qed jieħdu CRIXIVAN.
English: ANTIHISTAMINES Fexofenadine
Maltese: ANTI-ISTAMINI Fexofenadine
English: The maximum non-lethal oral dose of indinavir was at least 5,000 mg/kg in rats and mice, the highest dose tested in acute toxicity studies.
Maltese: Id-doża orali massima mhux letali ta' indinavir kienet mill-inqas 5,000 mg/kg fil-firien u l-ġrieden, logħla doża ttestjata fi studji dwar it-tossiċita` akuta.
English: printing ink: titanium dioxide (E 171), indigo carmine (E 132) and iron oxide (E 172).
Maltese: Kontenut tal-kapsula anhydrous lactose magnesium stearate qoxra tal-kapsula: ġelatina titanium dioxide (E 171) inka għall-istampar: titanium dioxide (E 171), indigo carmine (E 132) u iron oxide (E 172).
English: If a patient is already taking St. John's wort, stop St. John's wort, check viral levels and if possible indinavir levels.
Maltese: John's wort, ikkontrolla l-livelli virali u jekk jista' jkun il-livelli ta' indinavir levels.
English: The capsules are semi-translucent white and coded ‘CRIXIVAN 400 mg' in green.
Maltese: Il-kapsuli huma bojod semi-trasluċidi u kkodifikati ‘CRIXIVAN™ 400 mg' fl-aħdar.
English: EU/1/96/024/004 90 hard capsules EU/1/96/024/005 180 hard capsules
Maltese: EU/1/96/024/005 180 kapsula iebsa
English: Following a dose regimen of 800 mg every 8 hours, measured peak plasma concentrations (Cmax) after morning, afternoon and evening doses were 15,550 nM, 8,720 nM and 8,880 nM, respectively.
Maltese: Wara kura b'doża ta' 800 mg kull 8 sigħat, l-ogħla konċentrazzjonijiet imkejla tal-plażma (Cmax) wara d-dożi ta' filgħodu, ta' wara nofsinhar u ta' filgħaxija kienu ta' 15,550 nM, 8,720 nM u 8,880 nM, rispettivament.